Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 525 entries
Sorted by: Best Match Show Resources per page
Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid.

Proteomics. Clinical applications

Wei LN.
PMID: 26238624
Proteomics Clin Appl. 2009 Feb;3(2):279-85. doi: 10.1002/prca.200800100.

Testicular receptor 2 (TR2) belongs to the nuclear receptor superfamily that constitutes one of the largest transcription factor families. Due to the lack of specific ligands for TR2 and because TR2 gene knockout mice exhibited no apparent pathological phenotypes...

Cite
Wei LN. Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid. Proteomics Clin Appl. 2009;3(2):279-85doi: 10.1002/prca.200800100.
Wei, L. N. (2009). Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid. Proteomics. Clinical applications, 3(2), 279-85. https://doi.org/10.1002/prca.200800100
Wei, Li-Na. "Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid." Proteomics. Clinical applications vol. 3,2 (2009): 279-85. doi: https://doi.org/10.1002/prca.200800100
Wei LN. Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid. Proteomics Clin Appl. 2009 Feb;3(2):279-85. doi: 10.1002/prca.200800100. PMID: 26238624.
Copy Download .nbib Format: NLM
Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells.

Proteomics. Clinical applications

Brennan P, Shore AM, Clement M, Hewamana S, Jones CM, Giles P, Fegan C, Pepper C, Brewis IA.
PMID: 26238753
Proteomics Clin Appl. 2009 Mar;3(3):359-69. doi: 10.1002/prca.200800137.

B-lymphocytes are essential for the production of antibodies to fight pathogens and are the cells of origin in 95% of human lymphomas. During their activation, and immortalisation by Epstein-Barr virus (EBV) which contributes to human cancers, B-lymphocytes undergo dramatic...

Cite
Brennan P, Shore AM, Clement M, et al. Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics Clin Appl. 2009;3(3):359-69doi: 10.1002/prca.200800137.
Brennan, P., Shore, A. M., Clement, M., Hewamana, S., Jones, C. M., Giles, P., Fegan, C., Pepper, C., & Brewis, I. A. (2009). Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics. Clinical applications, 3(3), 359-69. https://doi.org/10.1002/prca.200800137
Brennan, Paul, et al. "Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells." Proteomics. Clinical applications vol. 3,3 (2009): 359-69. doi: https://doi.org/10.1002/prca.200800137
Brennan P, Shore AM, Clement M, Hewamana S, Jones CM, Giles P, Fegan C, Pepper C, Brewis IA. Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics Clin Appl. 2009 Mar;3(3):359-69. doi: 10.1002/prca.200800137. PMID: 26238753.
Copy Download .nbib Format: NLM
Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers.

Proteomics. Clinical applications

Sun W, Chen Y, Li F, Zhang L, Yang R, Zhang Z, Zheng D, Gao Y.
PMID: 26238754
Proteomics Clin Appl. 2009 Mar;3(3):370-82. doi: 10.1002/prca.200800061.

Human urinary proteome analysis is a convenient and efficient approach for understanding disease processes affecting the kidney and urogenital tract. Many potential biomarkers have been identified in previous differential analyses; however, dynamic variations of the urinary proteome have not...

Cite
Sun W, Chen Y, Li F, et al. Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers. Proteomics Clin Appl. 2009;3(3):370-82doi: 10.1002/prca.200800061.
Sun, W., Chen, Y., Li, F., Zhang, L., Yang, R., Zhang, Z., Zheng, D., & Gao, Y. (2009). Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers. Proteomics. Clinical applications, 3(3), 370-82. https://doi.org/10.1002/prca.200800061
Sun, Wei, et al. "Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers." Proteomics. Clinical applications vol. 3,3 (2009): 370-82. doi: https://doi.org/10.1002/prca.200800061
Sun W, Chen Y, Li F, Zhang L, Yang R, Zhang Z, Zheng D, Gao Y. Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers. Proteomics Clin Appl. 2009 Mar;3(3):370-82. doi: 10.1002/prca.200800061. PMID: 26238754.
Copy Download .nbib Format: NLM
Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome.

Proteomics. Clinical applications

Jackson D, Herath A, Swinton J, Bramwell D, Chopra R, Hughes A, Cheeseman K, Tonge R.
PMID: 26238755
Proteomics Clin Appl. 2009 Mar;3(3):394-407. doi: 10.1002/prca.200800066. Epub 2009 Feb 13.

Proteomics is increasingly being applied to the human plasma proteome to identify biomarkers of disease for use in non-invasive assays. 2-D DIGE, simultaneously analysing thousands of protein spots quantitatively and maintaining protein isoform information, is one technique adopted. Sufficient...

Cite
Jackson D, Herath A, Swinton J, et al. Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics Clin Appl. 2009;3(3):394-407doi: 10.1002/prca.200800066.
Jackson, D., Herath, A., Swinton, J., Bramwell, D., Chopra, R., Hughes, A., Cheeseman, K., & Tonge, R. (2009). Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics. Clinical applications, 3(3), 394-407. https://doi.org/10.1002/prca.200800066
Jackson, David, et al. "Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome." Proteomics. Clinical applications vol. 3,3 (2009): 394-407. doi: https://doi.org/10.1002/prca.200800066
Jackson D, Herath A, Swinton J, Bramwell D, Chopra R, Hughes A, Cheeseman K, Tonge R. Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics Clin Appl. 2009 Mar;3(3):394-407. doi: 10.1002/prca.200800066. Epub 2009 Feb 13. PMID: 26238755.
Copy Download .nbib Format: NLM
Diagnostic proteomics: will this impact the clinic?.

Proteomics. Clinical applications

Sauer S.
PMID: 24323456
Proteomics Clin Appl. 2013 Dec;7(11):725-6. doi: 10.1002/prca.201370063.

No abstract available.

Cite
Sauer S. Diagnostic proteomics: will this impact the clinic?. Proteomics Clin Appl. 2013;7(11):725-6doi: 10.1002/prca.201370063.
Sauer, S. (2013). Diagnostic proteomics: will this impact the clinic?. Proteomics. Clinical applications, 7(11), 725-6. https://doi.org/10.1002/prca.201370063
Sauer, Sascha. "Diagnostic proteomics: will this impact the clinic?." Proteomics. Clinical applications vol. 7,11 (2013): 725-6. doi: https://doi.org/10.1002/prca.201370063
Sauer S. Diagnostic proteomics: will this impact the clinic?. Proteomics Clin Appl. 2013 Dec;7(11):725-6. doi: 10.1002/prca.201370063. PMID: 24323456.
Copy Download .nbib Format: NLM
Paediatrics and proteomics: back to the beginning.

Proteomics. Clinical applications

Everett A, Ignjatovic V.
PMID: 25461013
Proteomics Clin Appl. 2014 Dec;8(11):805-6. doi: 10.1002/prca.201470064.

No abstract available.

Cite
Everett A, Ignjatovic V. Paediatrics and proteomics: back to the beginning. Proteomics Clin Appl. 2014;8(11):805-6doi: 10.1002/prca.201470064.
Everett, A., & Ignjatovic, V. (2014). Paediatrics and proteomics: back to the beginning. Proteomics. Clinical applications, 8(11), 805-6. https://doi.org/10.1002/prca.201470064
Everett, Allen, and Ignjatovic, Vera. "Paediatrics and proteomics: back to the beginning." Proteomics. Clinical applications vol. 8,11 (2014): 805-6. doi: https://doi.org/10.1002/prca.201470064
Everett A, Ignjatovic V. Paediatrics and proteomics: back to the beginning. Proteomics Clin Appl. 2014 Dec;8(11):805-6. doi: 10.1002/prca.201470064. PMID: 25461013.
Copy Download .nbib Format: NLM
Evolutionary medicine: A meaningful connection between omics, disease, and treatment.

Proteomics. Clinical applications

Abu-Asab M, Chaouchi M, Amri H.
PMID: 18458745
Proteomics Clin Appl. 2008 Feb;2(2):122-134. doi: 10.1002/prca.200780047.

The evolutionary nature of diseases requires that their omics be analyzed by evolution-compatible analytical tools such as parsimony phylogenetics in order to reveal common mutations and pathways' modifications. Since the heterogeneity of the omics data renders some analytical tools...

Cite
Abu-Asab M, Chaouchi M, Amri H. Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics Clin Appl. 2008;2(2):122-134doi: 10.1002/prca.200780047.
Abu-Asab, M., Chaouchi, M., & Amri, H. (2008). Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics. Clinical applications, 2(2), 122-134. https://doi.org/10.1002/prca.200780047
Abu-Asab, Mones, et al. "Evolutionary medicine: A meaningful connection between omics, disease, and treatment." Proteomics. Clinical applications vol. 2,2 (2008): 122-134. doi: https://doi.org/10.1002/prca.200780047
Abu-Asab M, Chaouchi M, Amri H. Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics Clin Appl. 2008 Feb;2(2):122-134. doi: 10.1002/prca.200780047. PMID: 18458745; PMCID: PMC2367146.
Copy Download .nbib Format: NLM
Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease.

Proteomics. Clinical applications

Park JY, Mun JH, Lee BH, Heo SH, Kim GH, Yoo HW.
PMID: 20556197
Proteomics Clin Appl. 2009 Oct;3(10):1185-1190. doi: 10.1002/prca.200800057.

Wilson's disease (WD) is characterized by excessive accumulation of intracellular copper in liver and extrahepatic tissues, leading to significant oxidative stress and tissue damage. To date, several diagnostic biomarkers for WD such as serum ceruloplasmin, serum or urine copper...

Cite
Park JY, Mun JH, Lee BH, et al. Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease. Proteomics Clin Appl. 2009;3(10):1185-1190doi: 10.1002/prca.200800057.
Park, J. Y., Mun, J. H., Lee, B. H., Heo, S. H., Kim, G. H., & Yoo, H. W. (2009). Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease. Proteomics. Clinical applications, 3(10), 1185-1190. https://doi.org/10.1002/prca.200800057
Park, Jung-Young, et al. "Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease." Proteomics. Clinical applications vol. 3,10 (2009): 1185-1190. doi: https://doi.org/10.1002/prca.200800057
Park JY, Mun JH, Lee BH, Heo SH, Kim GH, Yoo HW. Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease. Proteomics Clin Appl. 2009 Oct;3(10):1185-1190. doi: 10.1002/prca.200800057. PMID: 20556197; PMCID: PMC2883077.
Copy Download .nbib Format: NLM
Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.

Proteomics. Clinical applications

Li R, Guo Y, Han BM, Yan X, Utleg AG, Li W, Tu LC, Wang J, Hood L, Xia S, Lin B.
PMID: 20559448
Proteomics Clin Appl. 2008 Apr 01;2(4):543-555. doi: 10.1002/prca.200780159.

Expressed prostatic secretions (EPS) contain proteins of prostate origin that may reflect the health status of the prostate and be used as diagnostic markers for prostate diseases including prostatitis, benign prostatic hyperplasia, and prostate cancer. Despite their importance and...

Cite
Li R, Guo Y, Han BM, et al. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl. 2008;2(4):543-555doi: 10.1002/prca.200780159.
Li, R., Guo, Y., Han, B. M., Yan, X., Utleg, A. G., Li, W., Tu, L. C., Wang, J., Hood, L., Xia, S., & Lin, B. (2008). Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics. Clinical applications, 2(4), 543-555. https://doi.org/10.1002/prca.200780159
Li, Runsheng, et al. "Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates." Proteomics. Clinical applications vol. 2,4 (2008): 543-555. doi: https://doi.org/10.1002/prca.200780159
Li R, Guo Y, Han BM, Yan X, Utleg AG, Li W, Tu LC, Wang J, Hood L, Xia S, Lin B. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl. 2008 Apr 01;2(4):543-555. doi: 10.1002/prca.200780159. PMID: 20559448; PMCID: PMC2886281.
Copy Download .nbib Format: NLM
Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.

Proteomics. Clinical applications

Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K.
PMID: 20559449
Proteomics Clin Appl. 2009 Jul 01;3(7):853-861. doi: 10.1002/prca.200800141.

Epithelial ovarian cancer (EOC) ranks fifth as a cause of cancer deaths in women. Current diagnostic and monitoring markers have limited reliability for the detection of disease. We have tested the possibility of identifying candidate biomarkers present at low...

Cite
Lin B, White JT, Wu J, et al. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl. 2009;3(7):853-861doi: 10.1002/prca.200800141.
Lin, B., White, J. T., Wu, J., Lele, S., Old, L. J., Hood, L., & Odunsi, K. (2009). Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics. Clinical applications, 3(7), 853-861. https://doi.org/10.1002/prca.200800141
Lin, Biaoyang, et al. "Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer." Proteomics. Clinical applications vol. 3,7 (2009): 853-861. doi: https://doi.org/10.1002/prca.200800141
Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl. 2009 Jul 01;3(7):853-861. doi: 10.1002/prca.200800141. PMID: 20559449; PMCID: PMC2886282.
Copy Download .nbib Format: NLM
A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry.

Proteomics. Clinical applications

Patwa TH, Wang Y, Miller FR, Goodison S, Pennathur S, Barder TJ, Lubman DM.
PMID: 19194518
Proteomics Clin Appl. 2008;3(1):51-66. doi: 10.1002/prca.200800097.

An analysis of phosphorylation changes that occur during cancer progression would provide insights into the molecular pathways responsible for a malignant phenotype. In this study we employed a novel coupling of 2D-liquid separations and protein microarray technology to reveal...

Cite
Patwa TH, Wang Y, Miller FR, et al. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin Appl. 2008;3(1):51-66doi: 10.1002/prca.200800097.
Patwa, T. H., Wang, Y., Miller, F. R., Goodison, S., Pennathur, S., Barder, T. J., & Lubman, D. M. (2008). A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics. Clinical applications, 3(1), 51-66. https://doi.org/10.1002/prca.200800097
Patwa, Tasneem H, et al. "A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry." Proteomics. Clinical applications vol. 3,1 (2008): 51-66. doi: https://doi.org/10.1002/prca.200800097
Patwa TH, Wang Y, Miller FR, Goodison S, Pennathur S, Barder TJ, Lubman DM. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin Appl. 2008;3(1):51-66. doi: 10.1002/prca.200800097. PMID: 19194518; PMCID: PMC2633720.
Copy Download .nbib Format: NLM
Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability.

Proteomics. Clinical applications

Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA.
PMID: 20871745
Proteomics Clin Appl. 2009 Aug 01;3(8):874-882. doi: 10.1002/prca.200800001.

Instability of tissue protein biomarkers is a critical issue for molecular profiling. Pre-analytical variables during tissue procurement, such as time delays during which the tissue remains stored at room temperature, can cause significant variability and bias in downstream molecular...

Cite
Espina V, Mueller C, Edmiston K, et al. Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl. 2009;3(8):874-882doi: 10.1002/prca.200800001.
Espina, V., Mueller, C., Edmiston, K., Sciro, M., Petricoin, E. F., & Liotta, L. A. (2009). Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics. Clinical applications, 3(8), 874-882. https://doi.org/10.1002/prca.200800001
Espina, Virginia, et al. "Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability." Proteomics. Clinical applications vol. 3,8 (2009): 874-882. doi: https://doi.org/10.1002/prca.200800001
Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA. Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl. 2009 Aug 01;3(8):874-882. doi: 10.1002/prca.200800001. PMID: 20871745; PMCID: PMC2944287.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 525 entries